Blanco Ernesto J, Lane Andrew H, Aijaz Naghma, Blumberg Denise, Wilson Thomas A
Division of Pediatric Endocrinology, Department of Pediatrics, State University of New York, Stony Brook, NY 11794-8111, USA.
J Pediatr Endocrinol Metab. 2006 Jul;19(7):919-25. doi: 10.1515/jpem.2006.19.7.919.
Traditional methods for treating central diabetes insipidus during infancy, such as fluid therapy or the use of intranasal hormone replacement, have significant potential limitations. In a retrospective study of infants with diabetes insipidus, we examined outcome using subcutaneous (sc) DDAVP, and compared this to infants treated with intranasal lysine vasopressin or DDAVP. After in-patient dosage titration, outpatients' serum sodium concentrations were maintained in a narrower range in the sc group compared with the intranasal group, and the percentage of serum sodium concentrations within the normal range was greater in the sc group. There were no significant complications in either group. We conclude that DDAVP administered subcutaneously can be a safe and effective alternative to traditionally recommended treatments of central diabetes insipidus during infancy.
婴儿期中枢性尿崩症的传统治疗方法，如液体疗法或鼻内激素替代疗法，有显著的潜在局限性。在一项对尿崩症婴儿的回顾性研究中，我们研究了皮下注射去氨加压素（sc DDAVP）的治疗效果，并将其与接受鼻内赖氨酸加压素或去氨加压素治疗的婴儿进行比较。住院期间进行剂量滴定后，与鼻内给药组相比，皮下给药组门诊患者的血清钠浓度维持在更窄的范围内，且皮下给药组血清钠浓度在正常范围内的百分比更高。两组均无显著并发症。我们得出结论，皮下注射去氨加压素可作为婴儿期中枢性尿崩症传统推荐治疗方法的一种安全有效的替代方案。
